| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | FIBROGEN INC COM | 1,216,473 | 37,066,000 | 11.64% | ||
| 2 | FIVE PRIME THERAPEUTICS INC | 719,000 | 29,839,000 | 9.37% | ||
| 3 | JAZZ PHARMACEUTICALS PLC | 189,200 | 26,594,000 | 8.35% | Call | |
| 4 | RETROPHIN INC COM | 1,224,384 | 23,618,000 | 7.42% | ||
| 5 | ARRAY BIOPHARMA INC 3 06/01/2020 | 22,534 | 21,633,000 | 6.79% | PRN | |
| 6 | KURA ONCOLOGY INC | 2,450,000 | 20,580,000 | 6.46% | ||
| 7 | ASSEMBLY BIOSCIENCES INC | 2,098,302 | 15,758,000 | 4.95% | ||
| 8 | CYTOKINETICS INC | 1,418,700 | 14,840,000 | 4.66% | ||
| 9 | VALEANT PHARMACEUTICALS INTL | 126,500 | 12,859,000 | 4.04% | Call | |
| 10 | COLLEGIUM PHARMACEUTICAL INC COM | 465,118 | 12,791,000 | 4.02% | ||
| 11 | EPIZYME INC COM | 698,900 | 11,196,000 | 3.52% | ||
| 12 | GALAPAGOS NV | 167,361 | 10,524,000 | 3.31% | ||
| 13 | KITE PHARMA INCORPORATED | 166,000 | 10,229,000 | 3.21% | ||
| 14 | FLEX PHARMA INC COM | 795,088 | 9,899,000 | 3.11% | ||
| 15 | IRONWOOD PHARMACEUTICALS INC COM CL A | 821,531 | 9,522,000 | 2.99% | ||
| 16 | Nabriva Therapeutics AG | 838,680 | 7,931,000 | 2.49% | ||
| 17 | Life Technologies Corp | 790,462 | 7,770,000 | 2.44% | ||
| 18 | KINDRED BIOSCIENCES INC | 1,432,765 | 4,871,000 | 1.53% | ||
| 19 | RETROPHIN INC | 244,100 | 4,709,000 | 1.48% | Call | |
| 20 | CELLADON CORP | 2,843,170 | 4,179,000 | 1.31% | ||
| 21 | OVASCIENCE INC COM | 424,979 | 4,152,000 | 1.30% | ||
| 22 | GENVEC INC | 1,920,913 | 3,534,000 | 1.11% | ||
| 23 | CALITHERA BIOSCIENCES INC | 415,480 | 3,183,000 | 1.00% | ||
| 24 | CYTOKINETICS INC | 284,600 | 2,977,000 | 0.93% | Call | |
| 25 | ZAFGEN INC COM | 369,000 | 2,321,000 | 0.73% | ||
| 26 | FORWARD PHARMA A/S | 100,017 | 1,900,000 | 0.60% | ||
| 27 | AKARI THERAPEUTICS PLC | 100,750 | 1,461,000 | 0.46% | ||
| 28 | GILEAD SCIENCES INC | 11,800 | 1,194,000 | 0.38% | Call | |
| 29 | Nephrogenex Inc | 588,235 | 941,000 | 0.30% | ||
| 30 | QLT INC | 100,000 | 266,000 | 0.08% | ||
| 31 | ZAFGEN INC | 10,000 | 63,000 | 0.02% | Call |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001140361-16-052684, filed 2016.02.16).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
